Literature DB >> 2774485

Quantitation of cerebral atrophy in preclinical and end-stage Alzheimer's disease.

S M de la Monte1.   

Abstract

Morphometric analysis of standardized gross cerebral slices from 16 patients with end-stage Alzheimer's disease (AD), 14 controls without neuropathological lesions or neurological disease, and 4 neurologically intact nondemented patients with histopathological lesions of AD was used to measure cross-sectional areas of cerebral cortex, white matter, subcortical nuclei, and the ventricular system. In AD, there was global cerebral atrophy of both cortex and white matter, selective atrophy of the amygdala and hippocampus, and ex vacuo hydrocephalus. In addition, in half the cases of AD, white matter atrophy was associated with overt histopathological evidence of patchy rarefaction of fibers and gliosis. Patients with preclinical AD had prominent and selective shrinkage of white matter comparable to that observed in AD, yet their cortical areas were normal. These observations suggest that white matter degeneration is an intrinsic component of AD. Moreover, its presence in preclinical AD where cortical atrophy is not evident indicates that cytoskeletal abnormalities associated with axonal degeneration may precede and perhaps cause the cortical atrophy observed in clinically manifested AD.

Entities:  

Mesh:

Year:  1989        PMID: 2774485     DOI: 10.1002/ana.410250506

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  62 in total

Review 1.  Leuko-araiosis: a reappraisal. I. CT studies.

Authors:  D Inzitari; M Mascalchi
Journal:  Ital J Neurol Sci       Date:  1990-06

Review 2.  Metabolic Alterations Associated to Brain Dysfunction in Diabetes.

Authors:  João M N Duarte
Journal:  Aging Dis       Date:  2015-10-01       Impact factor: 6.745

3.  Differential Sphingolipid and Phospholipid Profiles in Alcohol and Nicotine-Derived Nitrosamine Ketone-Associated White Matter Degeneration.

Authors:  Emine B Yalcin; Kavin Nunez; Ming Tong; Suzanne M de la Monte
Journal:  Alcohol Clin Exp Res       Date:  2015-12       Impact factor: 3.455

4.  Aggregation of vascular risk factors and risk of incident Alzheimer disease.

Authors:  J A Luchsinger; C Reitz; L S Honig; M X Tang; Steven Shea; R Mayeux
Journal:  Neurology       Date:  2005-08-23       Impact factor: 9.910

5.  Clinical correlates of high signal lesions on magnetic resonance imaging in Alzheimer's disease.

Authors:  D A Bennett; D W Gilley; R S Wilson; M S Huckman; J H Fox
Journal:  J Neurol       Date:  1992-04       Impact factor: 4.849

6.  Neuropathological quantification of dtg APP/PS1: neuroimaging, stereology, and biochemistry.

Authors:  Kebreten F Manaye; Paul C Wang; Jahn N O'Neil; Sophia Y Huang; Tao Xu; De-Liang Lei; Yousef Tizabi; Mary Ann Ottinger; Donald K Ingram; Peter R Mouton
Journal:  Age (Dordr)       Date:  2007-08-03

Review 7.  Mechanisms of axonal injury: internodal nanocomplexes and calcium deregulation.

Authors:  David P Stirling; Peter K Stys
Journal:  Trends Mol Med       Date:  2010-03-06       Impact factor: 11.951

Review 8.  Relationships between diabetes and cognitive impairment.

Authors:  Suzanne M de la Monte
Journal:  Endocrinol Metab Clin North Am       Date:  2013-12-12       Impact factor: 4.741

9.  Altered temporal lobe white matter lipid ion profiles in an experimental model of sporadic Alzheimer's disease.

Authors:  Ming Tong; Raiane Leão; Gina V Vimbela; Emine B Yalcin; Jared Kay; Alexander Krotow; Suzanne M de la Monte
Journal:  Mol Cell Neurosci       Date:  2017-04-21       Impact factor: 4.314

10.  Clinico-pathological correlation in dementias.

Authors:  F Teixeira; E Alonso; V Romero; A Ortíz; C Martínez; E Otero
Journal:  J Psychiatry Neurosci       Date:  1995-07       Impact factor: 6.186

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.